m6A-centered Drug Response Information
General Information of the Drug (ID: M6APDG02047)
| Name |
Tenofovir
|
||||
|---|---|---|---|---|---|
| Synonyms |
(R)-9-(2-Phosphonomethoxypropyl)adenine; (R)-9-(2-Phosphonylmethoxypropyl)adenine; (R)-PMPA; Apropovir; D,L-Tenofovir; GNA & Tenofovir; GS 1275; GS 1278; GS1278; HHA & Tenofovir; KS-5021; PMPA; PMPA-(R); Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-& Galanthus nivalis agglutinin (GNA); Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-& Hippeastrum hybrid agglutinin(HHA); Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-(9CI); Phosphonic acid, [[2-(6-amino-9H-purin-9; TDF; TFV; Tenefovir; Viread (TN); Viread, Tenofovir; [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid
Click to Show/Hide
|
||||
| Status |
Approved
|
||||
| Structure |
 |
||||
| Formula |
C9H14N5O4P
|
||||
| InChI |
1S/C9H14N5O4P/c1-6(18-5-19(15,16)17)2-14-4-13-7-8(10)11-3-12-9(7)14/h3-4,6H,2,5H2,1H3,(H2,10,11,12)(H2,15,16,17)/t6-/m1/s1
|
||||
| InChIKey |
SGOIRFVFHAKUTI-ZCFIWIBFSA-N
|
||||
| PubChem CID | |||||
| VARIDT Drug ID | |||||
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Breast cancer resistance protein (ABCG2)
Methyltransferase-like 3 (METTL3)
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Tenofovir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tenofovir through regulating the expression of Breast cancer resistance protein (ABCG2). | [1], [2] | ||
Multidrug resistance-associated protein 7 (ABCC10)
Fat mass and obesity-associated protein (FTO)
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Multidrug resistance-associated protein 7 (ABCC10) is a therapeutic target for Tenofovir. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Tenofovir through regulating the expression of Multidrug resistance-associated protein 7 (ABCC10). | [3], [4] | ||
YTH domain-containing family protein 2 (YTHDF2)
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Multidrug resistance-associated protein 7 (ABCC10) is a therapeutic target for Tenofovir. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Tenofovir through regulating the expression of Multidrug resistance-associated protein 7 (ABCC10). | [3], [4] | ||
P-glycoprotein 1 (ABCB1)
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Tenofovir. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Tenofovir through regulating the expression of P-glycoprotein 1 (ABCB1). | [5], [6] | ||
Methyltransferase-like 3 (METTL3)
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Tenofovir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tenofovir through regulating the expression of P-glycoprotein 1 (ABCB1). | [1], [6] | ||
References